🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 41 of 55

  1. REGN5678

    Regeneron UK Limited

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  2. REGN7075

    Regeneron UK Limited

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  3. RELUGOLIX

    Fondazione Telethon ETS

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

  4. REOLYSIN

    ONCOLYTICS BIOTECH INC

    Metastatic or Recurrent Squamous Cell Carcinoma of the Lung

    phase 2 mab completed

    1 trial

  5. REOLYSIN

    ONCOLYTICS BIOTECH INC

    Metastatic Melanoma

    phase 2 mab completed

    1 trial

  6. REOLYSIN

    ONCOLYTICS BIOTECH INC

    Metastatic Pancreatic Adenocarcinoma

    phase 2 mab completed

    1 trial

  7. REOLYSIN®

    ONCOLYTICS BIOTECH INC

    Carcinoma, Non-small Cell Lung

    phase 2 mab completed

    1 trial

  8. REOLYSIN®

    ONCOLYTICS BIOTECH INC

    Osteosarcoma

    phase 2 mab completed

    1 trial

  9. RITUXIMAB , DOXORUBICIN , VINCRISTINE , IBRUTINIB , RITUXIMAB, PREDNISONE , CYCLOPHOSPHAMIDE

    Fondazione Telethon ETS

    Diffuse Large B-cell Lymphoma ABC

    phase 2 small molecule active

    1 trial

  10. RITUXIMAB, CYCLOPHOSPHAMIDE , AZD0486, PREDNISOLONE , VINCRISTINE , Calquence 100 mg film-coated tablets, RITUXIMAB , AZD0486, DOXORUBICIN , Calquence 100 mg film-coated tablets, PREDNISONE , AZD0486, AZD0486

    AstraZeneca AB

    Mantle Cell Lymphoma, Large B-Cell Lymphoma, Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  11. RITUXIMAB, Golcadomide

    Fondazione Telethon ETS

    Diffuse Large B-cells non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  12. RMC-4630

    Revolution Medicines

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  13. RMC-4630

    Revolution Medicines

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  14. RMC-6236

    Revolution Medicines

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  15. RMC-6236

    Revolution Medicines

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  16. RMC-9805

    Revolution Medicines

    Lung Cancer

    phase 2 small molecule active

    1 trial

  17. RO7197597

    Hoffmann-La Roche

    Grade 1 Endometrial Cancer

    phase 2 small molecule active

    1 trial

  18. RO7247669

    Hoffmann-La Roche

    Melanoma

    phase 2 small molecule completed

    1 trial

  19. RO7247669

    Hoffmann-La Roche

    Unresectable or Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  20. RO7790118, RO7791094, RO7790118, Tiragolumab, Avastin 25 mg/ml concentrate for solution for infusion., RO7247669, Tecentriq 1 200 mg concentrate for solution for infusion, RO7790118, TPST-1120, ADG126, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Advanced liver cancers

    phase 2 small molecule active

    1 trial

  21. RO7881583, EMPAGLIFLOZIN, Fulvestrant EVER Pharma 250 mg Injektionslösung in einer Fertigspritze, SACITUZUMAB GOVITECAN , Verzenios 100 mg film-coated tablets, EMPAGLIFLOZIN, PALBOCICLIB, INAVOLISIB, Tecentriq 1 200 mg concentrate for solution for infusion, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, PALBOCICLIB, PALBOCICLIB, RoActemra 20 mg/mL concentrate for solution for infusion, Kisqali 200 mg film-coated tablets, Verzenios 50 mg film-coated tablets, Tecentriq, Abraxane 5 mg/ml powder for di

    Hoffmann-La Roche

    Metastatic breast cancer, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)

    phase 2 small molecule active

    1 trial

  22. RUBIDIUM CHLORIDE

    Pari Pharma GmbH

    Kidney carcinoma

    phase 2 small molecule active

    1 trial

  23. RX-3117

    Processa Pharmaceuticals

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  24. RX-3117

    Processa Pharmaceuticals

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  25. Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine

    Hospital Authority, Hong Kong

    Advanced Tumors

    phase 2 other active

    1 trial

  26. Radio-guided sentinel node biopsy

    Hospital Authority, Hong Kong

    Cancer of the Breast

    phase 2 other terminated

    1 trial

  27. Radiochemoimmunotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  28. Radiotherapy

    The First People's Hospital of Lianyungang

    Cholangiocarcinoma

    phase 2 other terminated

    1 trial

  29. Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor

    The First People's Hospital of Lianyungang

    HER2-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  30. Radium-223 dichloride (Xofigo, BAY88-8223)

    Bayer HealthCare AG

    Breast Neoplasms

    phase 2 small molecule completed

    1 trial

  31. Raltitrexed

    The First People's Hospital of Lianyungang

    Inoperable Esophageal Cancer Stage I-III

    phase 2 small molecule active

    1 trial

  32. Raludotatug Deruxtecan

    Daiichi Sankyo

    Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)

    phase 2 small molecule active

    1 trial

  33. Raludotatug Deruxtecan (R-DXd)

    Merck KGaA, Darmstadt, Germany

    Gastrointestinal Cancer

    phase 2 mab active

    1 trial

  34. Ramucirumab

    Eli Lilly and Company

    Gastric Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  35. Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocrine tumors

    The George Institute

    Pancreatic well differentiated neuroendocrine tumors (NET)

    phase 2 other active

    1 trial

  36. Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu- edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospective, phase II trial

    Istituto Gentili S.r.l.

    NET, Neuroendocrine Tumor, Other SSTR-positive tumours, NETs retreated with PRRT, Pheochromocytomas and paragangliomas, Bronchopulmonary and other NETs

    phase 2 other active

    1 trial

  37. Recombinant Human Endostatin Injection

    The First People's Hospital of Lianyungang

    Locally Advanced Squamous Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  38. Recombinant anti-PD-1 humanized monoclonal antibody injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Sarcoma, Soft Tissue

    phase 2 small molecule active

    1 trial

  39. Recombinant human endostatin

    The First People's Hospital of Lianyungang

    Stage III Non-small-Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  40. Regorafenib

    United Therapeutics Europe Ltd

    Adenocarcinoma of the Gastroesophageal Junction

    phase 2 small molecule terminated

    1 trial

  41. Relacorilant

    CORCEPT THERAPEUTICS INC

    Recurrent Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  42. Relacorilant 150 mg once daily (QD)

    CORCEPT THERAPEUTICS INC

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  43. Relacorilant 150 mg once daily (QD)

    CORCEPT THERAPEUTICS INC

    Adenocarcinoma

    phase 2 small molecule active

    1 trial

  44. Relacorilant with nab-paclitaxel

    CORCEPT THERAPEUTICS INC

    Solid Tumors

    phase 2 small molecule completed

    1 trial

  45. Relatlimab

    Bristol-Myers Squibb

    Neoplasms by Site

    phase 2 mab completed

    1 trial

  46. Relugolix

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  47. Repotrectinib (TPX-0005)

    Turn Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  48. Repotrectinib (TPX-0005), Repotrectinib (TPX-0005), Repotrectinib (TPX-0005)

    Turn Therapeutics

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.